- Home
- IPSC vs CMRX Comparison
IPSC vs CMRX Comparison
Compare IPSC & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- CMRX
- Stock Information
- Founded
- IPSC 2019
- CMRX 2000
- Country
- IPSC United States
- CMRX United States
- Employees
- IPSC N/A
- CMRX N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- CMRX Health Care
- Exchange
- IPSC Nasdaq
- CMRX Nasdaq
- Market Cap
- IPSC 77.3M
- CMRX 77.1M
- IPO Year
- IPSC 2021
- CMRX 2013
- Fundamental
- Price
- IPSC $0.89
- CMRX $3.83
- Analyst Decision
- IPSC Strong Buy
- CMRX Strong Buy
- Analyst Count
- IPSC 4
- CMRX 2
- Target Price
- IPSC $11.00
- CMRX $8.50
- AVG Volume (30 Days)
- IPSC 562.3K
- CMRX 1.6M
- Earning Date
- IPSC 03-13-2025
- CMRX 02-27-2025
- Dividend Yield
- IPSC N/A
- CMRX N/A
- EPS Growth
- IPSC N/A
- CMRX N/A
- EPS
- IPSC N/A
- CMRX N/A
- Revenue
- IPSC $2,684,000.00
- CMRX $159,000.00
- Revenue This Year
- IPSC $230.51
- CMRX N/A
- Revenue Next Year
- IPSC $31.87
- CMRX $1,690.28
- P/E Ratio
- IPSC N/A
- CMRX N/A
- Revenue Growth
- IPSC 7.88
- CMRX N/A
- 52 Week Low
- IPSC $0.87
- CMRX $0.75
- 52 Week High
- IPSC $5.51
- CMRX $4.07
- Technical
- Relative Strength Index (RSI)
- IPSC 33.61
- CMRX 70.87
- Support Level
- IPSC $0.87
- CMRX $3.43
- Resistance Level
- IPSC $0.95
- CMRX $4.07
- Average True Range (ATR)
- IPSC 0.09
- CMRX 0.31
- MACD
- IPSC -0.00
- CMRX -0.04
- Stochastic Oscillator
- IPSC 11.39
- CMRX 74.74
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.